Psychopharmacology

, Volume 210, Issue 4, pp 471–480

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone

  • David Andrew Tompkins
  • Ryan K. Lanier
  • Joseph A. Harrison
  • Eric C. Strain
  • George E. Bigelow
Original Investigation

DOI: 10.1007/s00213-010-1838-3

Cite this article as:
Tompkins, D.A., Lanier, R.K., Harrison, J.A. et al. Psychopharmacology (2010) 210: 471. doi:10.1007/s00213-010-1838-3

Abstract

Rationale

Prescription opioid abuse has risen dramatically in the United States as clinicians have increased opioid prescribing for alleviation of both acute and chronic pain. Opioid analgesics with decreased risk for abuse are needed.

Objective

Preclinical and clinical studies have shown that opioids combined with ultra-low-dose naltrexone (NTX) may have increased analgesic potency and have suggested reduced abuse or dependence liability. This study addressed whether addition of ultra-low-dose naltrexone might decrease the abuse liability of oxycodone (OXY) in humans.

Materials and methods

This double-blind, placebo-controlled study systematically examined the subjective and physiological effects of combining oral OXY and ultra-low NTX doses in 14 experienced opioid abusers. Seven acute drug conditions given at least 5 days apart were compared in a within-subject crossover design: placebo, OXY 20 mg, OXY 40 mg, plus each of the active OXY doses combined with 0.0001 and 0.001 mg NTX.

Results

The methods were sensitive to detecting opioid effects on abuse liability indices, with significant differences between all OXY conditions and placebo as well as between 20 and 40 mg OXY doses on positive subjective ratings (e.g., “I feel a good drug effect” or “I like the drug”), on observer- and participant-rated opioid agonist effects, and on a drug-versus-money value rating. There were no significant differences or evident trends associated with the addition of either NTX dose on any abuse liability indices.

Conclusions

The addition of ultra-low-dose NTX to OXY did not decrease abuse liability of acutely administered OXY in experienced opioid abusers.

Keywords

Abuse liability Ultra-low-dose naltrexone Oxytrex OPIOID PTI-801 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • David Andrew Tompkins
    • 1
    • 3
  • Ryan K. Lanier
    • 1
    • 2
  • Joseph A. Harrison
    • 1
  • Eric C. Strain
    • 1
  • George E. Bigelow
    • 1
  1. 1.Department of Psychiatry and Behavioral SciencesJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Rock Creek Pharmaceuticals, Inc.GloucesterUSA
  3. 3.Behavioral Pharmacology Research UnitJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations